Search
Displaying 31–40 of 1146 results
-
Annual Funded Grants – CRISPR and Prime Editing Technologies
Research NewsFunded grants for CRISPR and prime editing approaches.
-
Eye on the Cure Podcast | Episode 93: Sam Seavey
Eye on the CureSam Seavey talks about his journey with Stargardt disease.
-
Watch Mike’s powerful story and see how your donation drives research toward treatments and cures for retinitis pigmentosa and blinding diseases. Donate today.
-
Built on Grit: Breaking Barriers to Employment
Beacon StoriesIn honor of National Disability Employment Awareness Month, we’re celebrating Mike Hess, founder of the Blind Institute of Technology (BIT). After years of being the “token blind guy” in the corporate world, Mike turned his experience into a movement for equity and opportunity—empowering blind, low vision, and disabled professionals with training, resources, and pathways to meaningful careers.
-
Foundation News
The free, online event at 7 p.m. ET on Tuesday, November 11, 2025, will feature presentations from patient advocate Jessie Wolinsky, retina specialist Sandeep Grover, MD, and clinical psychologist Ann Wagner, PhD, LP, ABPP.
-
Mental Health Statistics That You Should Know
WellnessShedding a light on some facts and figures that can help us understand the current state of our mental health and better provide support to the individuals who need it most.
-
Connecting and Empowering the Stargardt Community
A collaborative initiative from the Foundation Fighting Blindness and Alkeus Pharmaceuticals, bringing together education, storytelling, and shared experiences to inform and inspire those living with Stargardt disease.
-
Sepul Bio’s LCA10 RNA Therapy Moves into Phase 3 Clinical Trial
Research NewsThe emerging therapy improved vision for some participants in an earlier clinical trial.
-
Foundation Fighting Blindness Celebrates Blindness Awareness Month with #ShareYourVision Campaign
Foundation NewsThis social media campaign amplifies authentic stories from the blind and low vision community to highlight the spectrum of vision loss experiences.
-
Research News
Durable vision improvements were also observed out to 18 months for previously dosed adult patients in the trial.
.png)
